» Articles » PMID: 37851954

The Determinants of Elevated Pathobiological Determination of Atherosclerosis in Youth Risk Score in Perinatally HIV-Infected Adolescents in South Africa

Overview
Date 2023 Oct 18
PMID 37851954
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Youth living with perinatally acquired HIV infection (YLPHIV) are at risk of developing atherosclerotic cardiovascular disease.

Methods: We determined the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) coronary arteries (CA) and abdominal aorta (AA) risk scores among YLPHIV who are ≥15 years old in Cape Town Adolescent and Antiretroviral Cohort. PDAY score was calculated using non-high-density lipoprotein, high-density lipoprotein cholesterol, hyperglycemia, hypertension, obesity, and smoking; a score ≥1 was considered elevated. HIV viremia was categorized as sustained (SV) = viral load (VL) >50 copies/mL, transient (TV) = mix of VL >50 and ≤50 copies/mL, or sustained-virologic suppression = VL <50 copies/mL throughout the study. Among YLPHIV, logistic models were fit to assess factors associated with elevated PDAY.

Results: Overall, 218 YLPHIV [median age 16.8 (interquartile range: 15.9-17.8) years, male 47%] were included. Among YLPHIV, 8% (n = 17) had SV, and 54% (n = 118) had TV. Median antiretroviral therapy (ART) duration was 12 (interquartile range: 8-14) years. Among YLPHIV, 30.3% and 18.4% had elevated PDAY for CA and AA, respectively.Among YLPHIV, SV [adjusted odds ratio (aOR) = 18.4, P < 0.01] and TV (aOR = 2.10, P = 0.04) compared with virologic suppression and ART duration in years (aOR = 1.12, P = 0.03) were associated with elevated CA. Male sex was associated with both elevated CA and AA (aOR = 2.14, P = 0.02, and aOR = 3.43, P = 0.01, respectively) and association of SV with elevated AA (aOR = 3.24, P = 0.09).

Conclusions: A substantial proportion of YLPHIV have PDAY scores reflecting increased aggregate atherosclerotic risk. Among YLPHIV, viremia, lifetime ART duration, and male sex contribute to this risk, highlighting the importance of HIV control and the need to monitor cardiometabolic health.

Citing Articles

Subclinical Myocardial Fibrosis in South African Youth With HIV: Results From the CTAAC-Heart Study.

Jao J, Zar H, Kahts M, Jermy S, Egan D, Nyathi M Open Forum Infect Dis. 2024; 11(10):ofae555.

PMID: 39416995 PMC: 11482013. DOI: 10.1093/ofid/ofae555.

References
1.
Innes S, Abdullah K, Haubrich R, Cotton M, Browne S . High Prevalence of Dyslipidemia and Insulin Resistance in HIV-infected Prepubertal African Children on Antiretroviral Therapy. Pediatr Infect Dis J. 2015; 35(1):e1-7. PMC: 4707556. DOI: 10.1097/INF.0000000000000927. View

2.
Mahtab S, Zar H, Ntusi N, Joubert S, Asafu-Agyei N, Luff N . Endothelial Dysfunction in South African Youth Living With Perinatally Acquired Human Immunodeficiency Virus on Antiretroviral Therapy. Clin Infect Dis. 2020; 71(10):e672-e679. PMC: 7744981. DOI: 10.1093/cid/ciaa396. View

3.
Bitnun A, Sochett E, Dick P, To T, Jefferies C, Babyn P . Insulin sensitivity and beta-cell function in protease inhibitor-treated and -naive human immunodeficiency virus-infected children. J Clin Endocrinol Metab. 2004; 90(1):168-74. DOI: 10.1210/jc.2004-0125. View

4.
Piconi S, Parisotto S, Rizzardini G, Passerini S, Meraviglia P, Schiavini M . Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals. AIDS. 2012; 27(3):381-9. DOI: 10.1097/QAD.0b013e32835abcc9. View

5.
Dirajlal-Fargo S, McComsey G . Cardiometabolic Complications in Youth With Perinatally Acquired HIV in the Era of Antiretroviral Therapy. Curr HIV/AIDS Rep. 2021; 18(5):424-435. PMC: 8574078. DOI: 10.1007/s11904-021-00574-x. View